Kos Pharmaceuticals to Present at Deutsche Bank 2006 Healthcare Conference

Kos Pharmaceuticals, Inc., a leading specialty pharmaceutical company, will be presenting at the Deutsche Bank 2006 Healthcare Conference in Boston, MA. The presentation will take place on Wednesday, May 3, 2006 at 10:30 am ET and will be webcast live on the company's website. The conference will provide a platform for Kos to showcase its strong and growing research and development pipeline, including proprietary drug delivery technologies in solid-dose, inhalation, and aerosol metered-dose device administration.

Key Takeaways:

• Kos Pharmaceuticals will present at the Deutsche Bank 2006 Healthcare Conference on May 3, 2006, highlighting its research and development pipeline and proprietary drug delivery technologies.
• The company's principal product development strategy involves reformulating existing pharmaceutical products to improve safety, efficacy, and patient compliance.
• Kos' current product portfolio includes Niaspan(R) and Advicor(R) for cholesterol disorders, Azmacort(R) for asthma, Cardizem(R)LA for hypertension and angina, and Teveten(R) and Teveten(R)HCT for hypertension.
• The company's research and development pipeline includes proprietary drug delivery technologies in solid-dose, inhalation, and aerosol metered-dose device administration to fuel sustained, organic sales growth.
• Kos has a strong and growing research and development pipeline, which includes in-house and sponsored research, scientific in-licensing, and general corporate development activities.
• The company's strategy also involves making measured investments in new chemical entity research.
• Kos Pharmaceuticals is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing, and marketing proprietary prescription products for chronic diseases.

Statistics:

• The Deutsche Bank 2006 Healthcare Conference will take place on May 2-3, 2006, in Boston, MA.
• Sanjay Joshi, Corporate Vice President and Chief Information Officer, will oversee the company's webcast of the presentation.
• Kos Pharmaceuticals has a product portfolio of 6 products, including Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R), and Teveten(R)HCT.
• The company has a strong and growing research and development pipeline, with a focus on proprietary drug delivery technologies in solid-dose, inhalation, and aerosol metered-dose device administration.
• Kos Pharmaceuticals has a strong and growing R&D pipeline, with 5 main areas of focus: cardiovascular, metabolic, respiratory, general, and new chemical entity research.

Sources:

• Kos Pharmaceuticals Press Release, "Kos Pharmaceuticals, Inc. to Present at Deutsche Bank 2006 Healthcare Conference"
• Kos Pharmaceuticals Annual Report on Form 10-K for the year ended December 31, 2005
• Securities and Exchange Commission (SEC) filings
• Kos Pharmaceuticals website: www.kospharm.com